drugset / Trial / NCT04398927
Systemic Chemotherapy Plus PD-1 for Metastasis ICC
NaSingle-groupOpen-labelTreatment
Summary
This study were designed to verify the better method of survival for metastatic ICC. Since the traditional method for metastatic ICC was GEMOX(recommended from NCCN guideline), our previous study found better results from Folfirinox over GEMOX. Our current study were conducted for further investigation to verify the better method for metastatic ICC.
Timeline
- Start
- 2020-05-01
- Primary completion
- 2021-01-01
- Completion
- 2021-02-01
Outcome
Outcome not reported
Stopped (Enrollment): “no patient enrolled”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |
| Subject | fluorouracil | Small molecule | — | — |